Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor

Yu Tang Tung, Hsiao Ling Chen, Chih Ching Yen, Po Ying Lee, Hsin Chung Tsai, Ming Fong Lin, Chuan Mu Chen

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Lung cancers are among the most common cancers in the world, and the search for effective and safe drugs for the chemoprevention and therapy of pulmonary cancer has become important. In this study, bovine lactoferrin (bLF) was used in both in vitro and in vivo approaches to investigate its activity against lung cancer. A human lung cancer cell line, A549, which expresses a high level of vascular endothelial growth factor (VEGF) under hypoxia, was used as an in vitro system for bLF treatment. A strain of transgenic mice carrying the human VEGF-A165 (hVEGF-A165) gene, which induces pulmonary tumors, was used as an in vivo lung cancer therapy model. We found that bLF significantly decreased proliferation of A549 cells by decreasing the expression of VEGF protein in a dose-dependent manner. Furthermore, oral administration of bLF at 300mg/kg of body weight 3 times a week for 1.5 mo to the transgenic mice overexpressing hVEGF-A165 significantly eliminated expression of hVEGF-A165 and suppressed the formation of tumors. Additionally, treatment with bLF significantly decreased the levels of proinflammatory cytokines, such as tumor necrosis factor-α, and antiinflammatory cytokines, such as IL-4 and IL-10. Levels of IL-6, which is both a proinflammatory and an antiinflammatory cytokine, were also reduced. Treatment with bLF decreased levels of tumor necrosis factor-α, IL-4, IL-6, and IL-10 cytokines, resulting in limited inflammation, which then restricted growth of the lung cancer. Our results revealed that bLF is an inhibitor of angiogenesis and blocks lung cell inflammation; as such, it has considerable potential for therapeutic use in the treatment of lung cancer.

Original languageEnglish
Pages (from-to)2095-2106
Number of pages12
JournalJournal of Dairy Science
Volume96
Issue number4
DOIs
Publication statusPublished - Apr 2013
Externally publishedYes

Fingerprint

Lactoferrin
vascular endothelial growth factors
lactoferrin
lung neoplasms
Vascular Endothelial Growth Factor A
Lung Neoplasms
inflammation
Inflammation
cattle
Growth
cytokines
Cytokines
tumor necrosis factors
Interleukin-4
Interleukin-10
Transgenic Mice
interleukin-4
interleukin-10
Interleukin-6
interleukin-6

Keywords

  • Bovine lactoferrin
  • Pulmonary cancer
  • Transgenic mice
  • Vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

  • Animal Science and Zoology
  • Food Science
  • Genetics

Cite this

Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor. / Tung, Yu Tang; Chen, Hsiao Ling; Yen, Chih Ching; Lee, Po Ying; Tsai, Hsin Chung; Lin, Ming Fong; Chen, Chuan Mu.

In: Journal of Dairy Science, Vol. 96, No. 4, 04.2013, p. 2095-2106.

Research output: Contribution to journalArticle

Tung, Yu Tang ; Chen, Hsiao Ling ; Yen, Chih Ching ; Lee, Po Ying ; Tsai, Hsin Chung ; Lin, Ming Fong ; Chen, Chuan Mu. / Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor. In: Journal of Dairy Science. 2013 ; Vol. 96, No. 4. pp. 2095-2106.
@article{28c8a5225a9842c3a6fc13ac591ba936,
title = "Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor",
abstract = "Lung cancers are among the most common cancers in the world, and the search for effective and safe drugs for the chemoprevention and therapy of pulmonary cancer has become important. In this study, bovine lactoferrin (bLF) was used in both in vitro and in vivo approaches to investigate its activity against lung cancer. A human lung cancer cell line, A549, which expresses a high level of vascular endothelial growth factor (VEGF) under hypoxia, was used as an in vitro system for bLF treatment. A strain of transgenic mice carrying the human VEGF-A165 (hVEGF-A165) gene, which induces pulmonary tumors, was used as an in vivo lung cancer therapy model. We found that bLF significantly decreased proliferation of A549 cells by decreasing the expression of VEGF protein in a dose-dependent manner. Furthermore, oral administration of bLF at 300mg/kg of body weight 3 times a week for 1.5 mo to the transgenic mice overexpressing hVEGF-A165 significantly eliminated expression of hVEGF-A165 and suppressed the formation of tumors. Additionally, treatment with bLF significantly decreased the levels of proinflammatory cytokines, such as tumor necrosis factor-α, and antiinflammatory cytokines, such as IL-4 and IL-10. Levels of IL-6, which is both a proinflammatory and an antiinflammatory cytokine, were also reduced. Treatment with bLF decreased levels of tumor necrosis factor-α, IL-4, IL-6, and IL-10 cytokines, resulting in limited inflammation, which then restricted growth of the lung cancer. Our results revealed that bLF is an inhibitor of angiogenesis and blocks lung cell inflammation; as such, it has considerable potential for therapeutic use in the treatment of lung cancer.",
keywords = "Bovine lactoferrin, Pulmonary cancer, Transgenic mice, Vascular endothelial growth factor (VEGF)",
author = "Tung, {Yu Tang} and Chen, {Hsiao Ling} and Yen, {Chih Ching} and Lee, {Po Ying} and Tsai, {Hsin Chung} and Lin, {Ming Fong} and Chen, {Chuan Mu}",
year = "2013",
month = "4",
doi = "10.3168/jds.2012-6153",
language = "English",
volume = "96",
pages = "2095--2106",
journal = "Journal of Dairy Science",
issn = "0022-0302",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor

AU - Tung, Yu Tang

AU - Chen, Hsiao Ling

AU - Yen, Chih Ching

AU - Lee, Po Ying

AU - Tsai, Hsin Chung

AU - Lin, Ming Fong

AU - Chen, Chuan Mu

PY - 2013/4

Y1 - 2013/4

N2 - Lung cancers are among the most common cancers in the world, and the search for effective and safe drugs for the chemoprevention and therapy of pulmonary cancer has become important. In this study, bovine lactoferrin (bLF) was used in both in vitro and in vivo approaches to investigate its activity against lung cancer. A human lung cancer cell line, A549, which expresses a high level of vascular endothelial growth factor (VEGF) under hypoxia, was used as an in vitro system for bLF treatment. A strain of transgenic mice carrying the human VEGF-A165 (hVEGF-A165) gene, which induces pulmonary tumors, was used as an in vivo lung cancer therapy model. We found that bLF significantly decreased proliferation of A549 cells by decreasing the expression of VEGF protein in a dose-dependent manner. Furthermore, oral administration of bLF at 300mg/kg of body weight 3 times a week for 1.5 mo to the transgenic mice overexpressing hVEGF-A165 significantly eliminated expression of hVEGF-A165 and suppressed the formation of tumors. Additionally, treatment with bLF significantly decreased the levels of proinflammatory cytokines, such as tumor necrosis factor-α, and antiinflammatory cytokines, such as IL-4 and IL-10. Levels of IL-6, which is both a proinflammatory and an antiinflammatory cytokine, were also reduced. Treatment with bLF decreased levels of tumor necrosis factor-α, IL-4, IL-6, and IL-10 cytokines, resulting in limited inflammation, which then restricted growth of the lung cancer. Our results revealed that bLF is an inhibitor of angiogenesis and blocks lung cell inflammation; as such, it has considerable potential for therapeutic use in the treatment of lung cancer.

AB - Lung cancers are among the most common cancers in the world, and the search for effective and safe drugs for the chemoprevention and therapy of pulmonary cancer has become important. In this study, bovine lactoferrin (bLF) was used in both in vitro and in vivo approaches to investigate its activity against lung cancer. A human lung cancer cell line, A549, which expresses a high level of vascular endothelial growth factor (VEGF) under hypoxia, was used as an in vitro system for bLF treatment. A strain of transgenic mice carrying the human VEGF-A165 (hVEGF-A165) gene, which induces pulmonary tumors, was used as an in vivo lung cancer therapy model. We found that bLF significantly decreased proliferation of A549 cells by decreasing the expression of VEGF protein in a dose-dependent manner. Furthermore, oral administration of bLF at 300mg/kg of body weight 3 times a week for 1.5 mo to the transgenic mice overexpressing hVEGF-A165 significantly eliminated expression of hVEGF-A165 and suppressed the formation of tumors. Additionally, treatment with bLF significantly decreased the levels of proinflammatory cytokines, such as tumor necrosis factor-α, and antiinflammatory cytokines, such as IL-4 and IL-10. Levels of IL-6, which is both a proinflammatory and an antiinflammatory cytokine, were also reduced. Treatment with bLF decreased levels of tumor necrosis factor-α, IL-4, IL-6, and IL-10 cytokines, resulting in limited inflammation, which then restricted growth of the lung cancer. Our results revealed that bLF is an inhibitor of angiogenesis and blocks lung cell inflammation; as such, it has considerable potential for therapeutic use in the treatment of lung cancer.

KW - Bovine lactoferrin

KW - Pulmonary cancer

KW - Transgenic mice

KW - Vascular endothelial growth factor (VEGF)

UR - http://www.scopus.com/inward/record.url?scp=84875550832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875550832&partnerID=8YFLogxK

U2 - 10.3168/jds.2012-6153

DO - 10.3168/jds.2012-6153

M3 - Article

C2 - 23462173

AN - SCOPUS:84875550832

VL - 96

SP - 2095

EP - 2106

JO - Journal of Dairy Science

JF - Journal of Dairy Science

SN - 0022-0302

IS - 4

ER -